Yura
★    

Belarus,
2016-11-23 09:50
(2683 d 05:12 ago)

Posting: # 16808
Views: 4,928
 

 CI and alfa [RSABE / ABEL]

Dear All,
We spend in replicate design TRR / RTR / RRT three repeated measurements. Question: how to take the level of alpha and confidence interval for the point estimate calculation between measurements (T-R1, T-R2, R1-R2)? I assumed an alpha of 0.017 and CI 96.6. :confused:
Thanks for your comments in advance


Above - for Cmax. AUCt - without reference drug - Alpha 0.025 and CI 95,0?


Edit: Merged with a later post. You can edit your OP within 24 hours (see here). [Helmut]
ElMaestro
★★★

Denmark,
2016-11-24 22:35
(2681 d 16:26 ago)

@ Yura
Posting: # 16810
Views: 4,060
 

 CI and alfa

Hello Yura,

❝ We spend in replicate design TRR / RTR / RRT three repeated measurements. Question: how to take the level of alpha and confidence interval for the point estimate calculation between measurements (T-R1, T-R2, R1-R2)? I assumed an alpha of 0.017 and CI 96.6. :confused:


Something sounds a bit odd here. TRR/RTR/RRT with two different Ref's is not a replicate design; alpha adjustment is in that situation usually not what you want to do. But I would be entirely wrong, depending on the question you are actually asking in your trial. What is the purpose of the R1-R2 CI?

Let's get some more info. :-)

Pass or fail!
ElMaestro
Yura
★    

Belarus,
2016-11-25 08:51
(2681 d 06:10 ago)

@ ElMaestro
Posting: # 16811
Views: 4,163
 

 CI and alfa

Hello, ElMaestro
Design - partial replicate. Each volunteer experience once the tablet T and twice R. Receive individual BE. For the difference T - R (1) and T - R (2) is carried out and the point estimate is based CI. If extend beyond BE, using the R (1) - R (2) - to expand CI, but only for Cmax.
Thanks
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2016-11-25 14:00
(2681 d 01:01 ago)

@ Yura
Posting: # 16813
Views: 4,286
 

 iteratively adjusted α

Hi Yura,

since Belarus as a member of the EAEU (which in its GL closely followed the EMA’s rules for reference-scaling by Average Bioquivalence with Expanding Limits – ABEL), according “to the book” no adjustment of α is required (i.e., 90% CI of T vs. R).
However, when you suspect multiplicity issues – which might lead to an inflation of the Type I Error – you are right (Labes and Schütz1, Muñoz et al.2, Wonnemann et al.3)! Adjusting α in such a way that the consumer risk is preserved at 0.05 is provided in the open-source [image] package PowerTOST, function scABEL.ad().
No adjustment of α is required for PK metrics assessed by (conventional unscaled) ABE (like AUC). Adjustment for PK metrics intended for reference-scaling (like Cmax) depends on the CVwR and – to a minor degree – on the sample size. I would not recommend Bon­ferroni’s correction (i.e., α 0.025) because generally it is unnecessarily conservative and negatively impacts power. BTW, in rare cases (extremely high sample sizes) you would have to go below 0.025…


  1. Labes D, Schütz H. Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control. Pharm Res. 2016;33(11):2805–14. doi:10.1007/s11095-016-2006-1. full-text view-only.
  2. Muñoz J, Alcaide D, Ocaña J. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs. Stat Med. 2016;35(12):1933–43. doi:10.1002/sim.6834.
  3. Wonnemann M, Frömke C, Koch A. Inflation of the Type I Error: Investigations on Regulatory Recommendations for Bioequivalence of Highly Variable Drugs. Pharm Res. 2015;32(1):135–43. doi:10.1007/s11095-014-1450-z.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Yura
★    

Belarus,
2016-11-25 20:28
(2680 d 18:33 ago)

@ Helmut
Posting: # 16814
Views: 4,015
 

 iteratively adjusted α

thank you, Dear Helmut
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
113 visitors (0 registered, 113 guests [including 4 identified bots]).
Forum time: 15:02 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5